Avinger Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Avinger de 15.1% y 24.7% respectivamente, mientras que el BPA crecerá en un 66.4% al año.

Información clave

15.1%

Tasa de crecimiento de los beneficios

66.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	14.2%
Tasa de crecimiento de los ingresos	24.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:VG20 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	14	-13	N/A	N/A	1
12/31/2024	11	-15	N/A	N/A	1
12/31/2023	8	-17	N/A	N/A	1
9/30/2023	8	-19	-14	-14	N/A
6/30/2023	8	-22	-14	-14	N/A
3/31/2023	8	-22	-15	-15	N/A
12/31/2022	8	-27	-17	-17	N/A
9/30/2022	9	-28	-18	-18	N/A
6/30/2022	9	-29	-18	-18	N/A
3/31/2022	9	-27	-17	-17	N/A
12/31/2021	10	-22	-16	-16	N/A
9/30/2021	10	-21	-15	-15	N/A
6/30/2021	10	-21	-15	-15	N/A
3/31/2021	9	-22	-15	-15	N/A
12/31/2020	9	-23	-15	-15	N/A
9/30/2020	9	-23	-15	-15	N/A
6/30/2020	9	-23	-16	-16	N/A
3/31/2020	10	-24	-16	-16	N/A
12/31/2019	9	-23	-17	-17	N/A
9/30/2019	9	-24	-17	-18	N/A
6/30/2019	8	-25	-17	-17	N/A
3/31/2019	8	-26	-18	-18	N/A
12/31/2018	8	-36	-18	-18	N/A
9/30/2018	8	-39	-20	-20	N/A
6/30/2018	8	-43	-24	-24	N/A
3/31/2018	8	-49	-28	-28	N/A
12/31/2017	10	-49	-35	-34	N/A
9/30/2017	13	-52	-40	-40	N/A
6/30/2017	16	-55	N/A	-44	N/A
3/31/2017	18	-55	N/A	-50	N/A
12/31/2016	19	-56	N/A	-53	N/A
9/30/2016	17	-56	N/A	-54	N/A
6/30/2016	15	-56	N/A	-55	N/A
3/31/2016	13	-53	N/A	-49	N/A
12/31/2015	11	-50	N/A	-41	N/A
9/30/2015	11	-44	N/A	-35	N/A
6/30/2015	11	-40	N/A	-28	N/A
3/31/2015	11	-37	N/A	-24	N/A
12/31/2014	11	-32	N/A	-22	N/A
9/30/2014	12	-32	N/A	-23	N/A
6/30/2014	12	-33	N/A	-27	N/A
3/31/2014	12	-37	N/A	-34	N/A
12/31/2013	13	-40	N/A	-41	N/A
12/31/2012	9	-34	N/A	-35	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VG20 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que VG20 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que VG20 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (24.7% al año) de VG20 crezcan más rápidamente que los del mercado German (5.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (24.7% al año) de VG20 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VG20 se prevé que sea elevada dentro de 3 años.

Avinger Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.94 loss in 2Q 2022)

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings released: US$0.71 loss per share (vs US$2.33 loss in 1Q 2022)

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$0.73 loss in 2Q 2021)

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.33 loss in 1Q 2021)

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €1.81

Avinger Regains Compliance with Nasdaq Listing Requirements

New 90-day high: €1.36

New 90-day high: €0.44

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Revenue beats expectations

Third quarter 2020 earnings released: US$0.079 loss per share

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - €0.58

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento